Pharmacokinetic Study Of EPZICOM Tablet
HIV Infection

About this trial
This is an interventional treatment trial for HIV Infection focused on measuring EPZICOM, Lamivudine, Abacavir, pharmacokinetics, Japanese
Eligibility Criteria
Inclusion criteria: A Japanese HIV-infected patient who continues to use one EPZICOM tablet in the morning (00:00 to 12:00) at least for 2 weeks prior to administration of the study drug. A patient who agrees to abstain from alcohol from 48 hours prior to administration of the study drug until completion of blood sampling for pharmacokinetic analysis. Exclusion criteria: A patient developing AIDS (Patients who developed AIDS in the past but have no symptoms or findings that may serve as indicators at screening may be eligible for the study.) A patient with a history of hypersensitivity to the study drug and the ingredients (lamivudine, abacavir sulfate) of the study drug
Sites / Locations
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site
- GSK Investigational Site